The safe drinking limit recommended by the BMA for both men and women is 21 U per week.

Alcohol Units and Safe Drinking Limits in the UK

The issue of safe drinking limits is a controversial one, with different bodies having different recommendations. In the UK, recommendations are sometimes given in grams of pure alcohol, with one unit equaling 8g. The UK government first recommended in 1992 that for a single week, 21 units for men and 14 units for women was the safe drinking limit. However, in 1995 they produced a report called ‘sensible drinking’, which effectively raised the weekly limits to 28 units for men and 21 units for women. The British Medical Association (BMA) responded to this change, along with the Royal College of Psychiatrists, saying that the original limits should not be relaxed.

In August 2016, the UK Chief Medical Officers Low Risk Drinking Guidelines revised the limits down so that the upper safe limit is now 14 units for both men and women. The Royal College of Psychiatrists welcomed this new guidance, stating that both men and women drinking less than 14 units of alcohol per week (around 7 pints of ordinary strength beer) will be at a low risk for illnesses like heart disease, liver disease, of cancer. However, for people who do drink, they should have three of more alcohol-free days to allow their bodies the opportunity to recover from the harmful effects of alcohol. The BMA also supports this new guidance.

Schizophrenia and Cannabis Use

The relationship between cannabis use and the risk of developing schizophrenia is a topic of ongoing debate. However, research suggests that cannabis use may increase the risk of later schizophrenia of schizophreniform disorder by two-fold (Arseneault, 2004). The risk of developing schizophrenia appears to be higher in individuals who start using cannabis at a younger age. For instance, regular cannabis smokers at the age of 15 are 4.5 times more likely to develop schizophrenia at the age of 26, compared to those who did not report regular use until age 18 (Murray, 2004).

A systematic review published in the Lancet in 2007 found that the lifetime risk of developing psychosis increased by 40% in individuals who had ever used cannabis (Moore, 2007). Another meta-analysis reported that the age at onset of psychosis was 2.70 years younger in cannabis users than in non-users (Large, 2011). These findings suggest that cannabis use may have a significant impact on the development of schizophrenia and related disorders.

Delirium tremens (DTs) is a serious medical emergency that can occur in individuals who abruptly reduce their alcohol intake after prolonged excessive drinking. It is estimated that 24% of adults in the UK drink in a hazardous way, with the highest rates in the North East, North West, and Yorkshire and Humber regions. About 20% of patients admitted to hospital for non-alcohol-related illnesses are also drinking at potentially hazardous levels, highlighting the importance of screening all patients for alcohol use.

Withdrawal symptoms typically appear about 8 hours after a significant drop in blood alcohol levels, with the peak occurring on day two and significant improvement by day five. Minor withdrawal symptoms include insomnia, fatigue, tremors, anxiety, nausea, vomiting, headache, sweating, palpitations, anorexia, depression, and craving. Alcoholic hallucinosis can occur 12-24 hours after stopping alcohol and involves visual, auditory, and tactile hallucinations. Withdrawal seizures can occur 24-48 hours after cessation and are generalized tonic-clonic seizures. DTs can occur 48-72 hours after cessation and is characterized by altered mental status, hallucinations, confusion, delusions, severe agitation, and seizures. It is a hyperadrenergic state and is often associated with tachycardia, hyperthermia, hypertension, tachypnea, tremor, and mydriasis. Patients at increased risk include those with a previous history of DTs of alcohol withdrawal seizures, co-existing infections, abnormal liver function, and older patients.

DTs should be treated as a medical emergency with oral lorazepam as first-line treatment. If symptoms persist of medication is refused, parenteral lorazepam, haloperidol, of olanzapine should be given. Intensive care may be required. If DTs develop during treatment for acute withdrawal, the reducing regime should be reviewed. The mortality rate can be up to 35% if untreated, which reduces to 5% with early recognition and treatment.

Patients with alcohol withdrawal seizures should be given a quick-acting benzodiazepine such as lorazepam. Phenytoin should not be given. Patients at high risk of alcohol withdrawal but with no of mild symptoms are typically given a reducing dose of chlordiazepoxide of diazepam over 5-7 days. Chlormethiazole may also be offered as an alternative, but is rarely used due to the risk of fatal respiratory depression, especially in patients with liver cirrhosis.

It is also important to administer high-potency B vitamins, specifically thiamine (e.g. pabrinex), to all patients with a history of high alcohol intake to reduce the risk of Wernicke’s encephalopathy.

Drug Misuse (Law and Scheduling)

The Misuse of Drugs Act (1971) regulates the possession and supply of drugs, classifying them into three categories: A, B, and C. The maximum penalty for possession varies depending on the class of drug, with Class A drugs carrying a maximum sentence of 7 years.

The Misuse of Drugs Regulations 2001 further categorizes controlled drugs into five schedules. Schedule 1 drugs are considered to have no therapeutic value and cannot be lawfully possessed of prescribed, while Schedule 2 drugs are available for medical use but require a controlled drug prescription. Schedule 3, 4, and 5 drugs have varying levels of restrictions and requirements.

It is important to note that a single drug can have multiple scheduling statuses, depending on factors such as strength and route of administration. For example, morphine and codeine can be either Schedule 2 of Schedule 5.

Overall, the Misuse of Drugs Act and Regulations aim to regulate and control the use of drugs in the UK, with the goal of reducing drug misuse and related harm.

Opioid Maintenance Therapy and Detoxification

Withdrawal symptoms can occur after as little as 5 days of regular opioid use. Short-acting opioids like heroin have acute withdrawal symptoms that peak in 32-72 hours and last for 3-5 days. Longer-acting opioids like methadone have acute symptoms that peak at day 4-6 and last for 10 days. Buprenorphine withdrawal lasts up to 10 days and includes symptoms like myalgia, anxiety, and increased drug craving.

Opioids affect the brain through opioid receptors, with the µ receptor being the main target for opioids. Dopaminergic cells in the ventral tegmental area produce dopamine, which is released into the nucleus accumbens upon stimulation of µ receptors, producing euphoria and reward. With repeat opioid exposure, µ receptors become less responsive, causing dysphoria and drug craving.

Methadone and buprenorphine are maintenance-oriented treatments for opioid dependence. Methadone is a full agonist targeting µ receptors, while buprenorphine is a partial agonist targeting µ receptors and a partial k agonist of functional antagonist. Naloxone and naltrexone are antagonists targeting all opioid receptors.

Methadone is preferred over buprenorphine for detoxification, and ultra-rapid detoxification should not be offered. Lofexidine may be considered for mild of uncertain dependence. Clonidine and dihydrocodeine should not be used routinely in opioid detoxification. The duration of detoxification should be up to 4 weeks in an inpatient setting and up to 12 weeks in a community setting.

Pregnant women dependent on opioids should use opioid maintenance treatment rather than attempt detoxification. Methadone is preferred over buprenorphine, and transfer to buprenorphine during pregnancy is not advised. Detoxification should only be considered if appropriate for the women’s wishes, circumstances, and ability to cope. Methadone or buprenorphine treatment is not a contraindication to breastfeeding.

Individuals who have ingested PCP often exhibit difficulty with coordination and speech. The hallucinations experienced are typically intricate rather than straightforward. It is more likely for them to have excessive saliva production rather than a dry mouth.

PCP Intoxication: A Dangerous Hallucinogenic

Phencyclidine (PCP), also known as angel dust, is a hallucinogenic drug that is popular for inducing feelings of euphoria, superhuman strength, and social and sexual prowess. It is a NMDA receptor antagonist that has dissociative properties, similar to ketamine. PCP was previously used as an anesthetic and animal tranquilizer, but was soon recalled due to its adverse effects, including psychosis, agitation, and dysphoria post-operatively.

PCP is available in various forms, including white crystalline powder, tablets, crystals, and liquid. It can be snorted, smoked, ingested, of injected intravenously or subcutaneously. People who have taken PCP often present with violent behavior, nystagmus, tachycardia, hypertension, anesthesia, and analgesia. Other symptoms include impaired motor function, hallucinations, delusions, and paranoia.

PCP intoxication is best managed with benzodiazepines along with supportive measures for breathing and circulation. Antipsychotics are not recommended as they can amplify PCP-induced hyperthermia, dystonic reactions, and lower the seizure threshold. However, haloperidol may be useful for treating PCP-induced psychosis in patients who are not hyperthermic. Most deaths in PCP-intoxicated patients result from violent behavior rather than direct effects of the drug.

A diagnosis of alcohol use disorder only requires the presence of two or more of the 11 elements, including withdrawal and recurrent alcohol use in physically hazardous situations. Ongoing craving for alcohol does not prevent someone from being considered in sustained remission, which is defined as not meeting any criteria for alcohol use disorder for 12 months of longer, except for craving. Monitoring abstinence can be done using state markers such as GGT and CDT levels, which return to normal within days to weeks of stopping drinking, but MCV is a poor method due to the long half-life of red blood cells. Increases in GGT and CDT levels over time may indicate a return to heavy drinking.

Alcohol Dependence Syndrome: ICD-11 and DSM 5 Criteria

The criteria for diagnosing alcohol dependence syndrome in the ICD-11 and DSM 5 are quite similar, as both are based on the original concept developed by Edwards and Gross in 1976. The original concept had seven elements, including narrowing of the drinking repertoire, salience of drink seeking behavior, tolerance, withdrawal symptoms, relief of withdrawal by further drinking, compulsion to drink, and rapid reinstatement of symptoms after a period of abstinence.

The DSM-5 Alcohol Use Disorder criteria include a problematic pattern of alcohol use leading to clinically significant impairment of distress, as manifested by at least two of the following occurring within a 12-month period. These include taking alcohol in larger amounts of over a longer period than intended, persistent desire of unsuccessful efforts to cut down of control alcohol use, spending a great deal of time in activities necessary to obtain alcohol, craving of a strong desire of urge to use alcohol, recurrent alcohol use resulting in a failure to fulfill major role obligations, continued alcohol use despite having persistent or recurrent social of interpersonal problems, giving up of reducing important social, occupational, of recreational activities due to alcohol use, recurrent alcohol use in physically hazardous situations, and continued alcohol use despite knowledge of having a persistent or recurrent physical or psychological problem caused or exacerbated by alcohol. Tolerance and withdrawal symptoms are also included in the criteria.

The ICD-11 Alcohol Dependence criteria include a pattern of recurrent episodic of continuous use of alcohol with evidence of impaired regulation of alcohol use, manifested by impaired control over alcohol use, increasing precedence of alcohol use over other aspects of life, and physiological features indicative of neuroadaptation to the substance, including tolerance to the effects of alcohol of a need to use increasing amounts of alcohol to achieve the same effect, withdrawal symptoms following cessation of reduction in use of alcohol, of repeated use of alcohol of pharmacologically similar substances to prevent of alleviate withdrawal symptoms. The features of dependence are usually evident over a period of at least 12 months, but the diagnosis may be made if use is continuous for at least 3 months.

Drug Misuse (Law and Scheduling)

The Misuse of Drugs Act (1971) regulates the possession and supply of drugs, classifying them into three categories: A, B, and C. The maximum penalty for possession varies depending on the class of drug, with Class A drugs carrying a maximum sentence of 7 years.

The Misuse of Drugs Regulations 2001 further categorizes controlled drugs into five schedules. Schedule 1 drugs are considered to have no therapeutic value and cannot be lawfully possessed of prescribed, while Schedule 2 drugs are available for medical use but require a controlled drug prescription. Schedule 3, 4, and 5 drugs have varying levels of restrictions and requirements.

It is important to note that a single drug can have multiple scheduling statuses, depending on factors such as strength and route of administration. For example, morphine and codeine can be either Schedule 2 of Schedule 5.

Overall, the Misuse of Drugs Act and Regulations aim to regulate and control the use of drugs in the UK, with the goal of reducing drug misuse and related harm.

Korsakoff’s Syndrome

Korsakoff’s Syndrome, also known as amnesic syndrome, is a chronic condition that affects recent and anterograde memory in an alert and responsive patient. It is caused by prolonged thiamine (vitamin B1) deficiency and often follows Wernicke’s encephalopathy. The syndrome is characterized by a lack of insight, apathy, and confabulation. Thiamine is essential for glucose metabolism in the brain, and its deficiency leads to a toxic buildup of glucose, causing neuronal loss. The Mammillary bodies are the main areas affected in Korsakoff’s syndrome.

While intelligence on the WAIS is preserved, episodic memory is severely affected in Korsakoff’s syndrome. Semantic memory is variably affected, but implicit aspects of memory, such as response to priming and procedural memory, are preserved. Immediate memory tested with the digit span is normal, but information can only be retained for a few minutes at most. Patients with Korsakoff’s syndrome often display apathy, lack of initiative, and profound lack of insight.

Source: Kopelman M (2009) The Korsakoff Syndrome: Clinical Aspects, Psychology and Treatment. Alcohol and Alcoholism 44 (2): 148-154.

The latest LSD immunoassays are created to detect 2-oxo-3-hydroxy-LSD, the main metabolite that can be found in higher concentrations in urine, potentially enhancing the accuracy of detection.

Drug Screening

Drug testing can be conducted through various methods, but urinalysis is the most common. Urine drug tests can be either screening of confirmatory. Screening tests use enzymatic immunoassays to detect drug metabolites of classes of drug metabolites in the urine. However, these tests have limitations, such as false positives due to cross-reactivity. Therefore, any positive test should be confirmed through gas chromatography of mass spectrometry.

People may try to manipulate drug testing procedures by adulterating the sample. Normal urine parameters, such as temperature, specific gravity, and pH, can assist in detecting adulterated samples. Adulterants include household items like vinegar, detergent, and ammonia, as well as commercially available products. Diluted urine may also yield false negatives.

Detection times vary from person to person, and the approximate drug detection time in urine can be found in a table provided by Nelson (2016). False positives can occur due to cross-reactivity, as illustrated by Moeller (2017). Clinicians should be aware of the limitations of urine drug tests and the potential for manipulation.